Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 61 of 114

  1. MET55

    Sanofi Pasteur

    Meningococcal Immunization

    phase 3 mab completed

    1 trial

  2. METFORMIN

    Pari Pharma GmbH

    Type 2 Diabetes complete remission after bariatric surgery under antidiabetic drug

    phase 3 small molecule active

    1 trial

  3. METFORMIN , DAPAGLIFLOZIN

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  4. METFORMIN for PASC: post-acute sequelae of SARS-CoV-2 infection

    Disc Medicine

    PASC: post-acute sequelae of SARS-CoV-2 infection

    phase 3 small molecule active

    1 trial

  5. METFORMIN, COLCHICINE

    Disc Medicine

    PASC: post-acute sequelae of SARS-CoV-2 infection

    phase 3 small molecule active

    1 trial

  6. METHOTREXATE for Immune system disorders

    Pari Pharma GmbH

    Immune system disorders

    phase 3 small molecule active

    1 trial

  7. METHYLPREDNISOLONE , ACETYLCYSTEINE

    The George Institute

    Acute Alcoholic hepatitis

    phase 3 small molecule active

    1 trial

  8. MEX-DM-302

    Lupin Europe GmbH

    Myotonic Dystrophy type 1 and type 2 (DM1/DM2)

    phase 3 small molecule active

    1 trial

  9. MEX-DM-303

    Lupin Europe GmbH

    Myotonic Dystrophy type 1 and type 2 (DM1/DM2)

    phase 3 small molecule active

    1 trial

  10. MEX-NDM-301

    Lupin Europe GmbH

    Non-Dystrophic Myotonias (NDM)

    phase 3 small molecule active

    1 trial

  11. MG0014

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  12. MG0015

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  13. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    NASH - Nonalcoholic Steatohepatitis

    phase 3 small molecule active

    1 trial

  14. MGL-3196-11

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  15. MGL-3196-19

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis (NASH) Cirrhosis

    phase 3 small molecule active

    1 trial

  16. MGT-RPGR-022

    Janssen-Cilag International N.V.

    X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene

    phase 3 small molecule active

    1 trial

  17. MHICC-2021-001

    The George Institute

    Type 2 diabetic patients with no prior cardiovascular (CV) events

    phase 3 small molecule active

    1 trial

  18. MICROPREP III

    ISTA Pharma Limited

    knee osteoarthritis

    phase 3 other active

    1 trial

  19. MIE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Carcinoma

    phase 3 other active

    1 trial

  20. MIN-003-1806

    Lacuna Pharma Pty Ltd

    Newly diagnosed primary glioblastoma multiforme (ndGBM)

    phase 3 small molecule active

    1 trial

  21. MINJUVI 200 mg powder for concentrate for solution for infusion

    Incyte

    Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimmune hemolytic anemia

    phase 3 small molecule active

    1 trial

  22. MITAPIVAT, Placebo for Mitapivat

    Lacuna Pharma Pty Ltd

    Transfusion-Dependent Alpha- or Beta-Thalassemia

    phase 3 small molecule active

    1 trial

  23. MITO 33

    Fondazione Telethon ETS

    Recurrent ovarian, fallopian tube or primary peritoneal cancer

    phase 3 small molecule active

    1 trial

  24. MK-0616

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  25. MK-0616, Placebo to MK-0616

    Merck Sharp and Dohme

    ​Heterozygous Familial Hypercholesterolemia​ in pediatric patients

    phase 3 small molecule active

    1 trial

  26. MK-0616, Placebo to MK-0616 - Tablet

    Merck Sharp and Dohme

    ASCVD - Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  27. MK-0616-013

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  28. MK-0616-018

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  29. MK-0616-037

    Merck Sharp and Dohme

    Hyperlipidemia

    phase 3 small molecule active

    1 trial

  30. MK-1022-016

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  31. MK-1026-011

    Merck Sharp and Dohme

    Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  32. MK-1026-011

    Merck Sharp and Dohme

    Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  33. MK-1084-004

    Merck Sharp and Dohme

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  34. MK-1084-007

    Merck Sharp and Dohme

    Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC

    phase 3 small molecule active

    1 trial

  35. MK-1084-012

    Merck Sharp and Dohme

    KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  36. MK-1084-013

    Merck Sharp and Dohme

    Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC

    phase 3 small molecule active

    1 trial

  37. MK-1242-043

    Merck Sharp and Dohme

    Heart Failure due to Systemic Left Ventricular Systolic Dysfunction

    phase 3 small molecule active

    1 trial

  38. MK-2140-010

    Merck Sharp and Dohme

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  39. MK-2400-001

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  40. MK-2870-005

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  41. MK-2870-007

    Merck Sharp and Dohme

    Metastatic non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  42. MK-2870-009

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  43. MK-2870-010

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  44. MK-2870-011

    Merck Sharp and Dohme

    Locally recurrent unresectable or metastatic TNBC with tumors expressing PD-L1 at the cut-off of CPS <10

    phase 3 small molecule active

    1 trial

  45. MK-2870-012

    Merck Sharp and Dohme

    Triple negative breast cancer.

    phase 3 small molecule active

    1 trial

  46. MK-2870-015

    Merck Sharp and Dohme

    advanced or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma

    phase 3 small molecule active

    1 trial

  47. MK-2870-019

    Merck Sharp and Dohme

    Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB (with nodal involvement [N2])

    phase 3 small molecule active

    1 trial

  48. MK-2870-020

    Merck Sharp and Dohme

    Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy.

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.